Regeneron (REGN) Tops Q1 EPS by 20c; Boosts U.S. EYLEA Sales Outlook

May 7, 2015 6:34 AM EDT

Regeneron (NASDAQ: REGN) reported Q1 EPS of $2.88, $0.20 better than the analyst estimate of $2.68. Revenue for the quarter came in at $870 million versus the consensus estimate of $820.3 million.

Net product sales were $545 million in the first quarter of 2015, compared to $362 million in the first quarter of 2014. EYLEA net product sales in the United States were $541 million in the first quarter of 2015, compared to $359 million in the first quarter of 2014.

2015 Financial Guidance

The Company's updated full year 2015 financial guidance consists of the following components:

EYLEA U.S. net product sales

30% - 35% growth over 2014

(previously 25% - 30% growth over 2014)

Non-GAAP unreimbursed R&D (2)

$525 million - $575 million (reaffirmed)

Non-GAAP SG&A (2)

$650 million - $725 million (reaffirmed)

Cash tax as a % of non-GAAP pre-tax income (2)

10% - 20% (reaffirmed)

Capital expenditures

$650 million - $750 million

(previously $650 million - $800 million)

For earnings history and earnings-related data on Regeneron (REGN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings